Introduction
Wound healing is a dynamic interactive and complex process involving soluble mediators, blood cells, extracellular matrix, and parenchymal cells. 1 Different cell types synthesize and release different mediators that modulate and stimulate the cascade of wound healing. These mediators encompass multiple chemokines and growth factors. Particularly growth factors have been suggested to influence and modulate epidermal and dermal regeneration. 1, 2 As dermal and epidermal regeneration has been shown to be crucial for survival of many pathophysiologic states, such as burns, an accelerated rate of wound healing would be beneficial. A growth factor that has been shown to improve wound healing is keratinocyte growth factor (KGF).
3,4 KGF a 26-28-kDa protein is a member of the fibroblast growth factor (FGF) 5 and is mainly synthesized in various types of mesenchymal cells, such as fibroblasts, microvascular endothelial cells 6 and smooth muscle cells. 7 KGF has not been shown to be expressed in cells of epithelial origin. 3, 4 In vitro studies demonstrated that KGF exerts its effects mainly in a paracrine fashion and is essential for skin morphogenesis. 3, 8 KGF has been shown to stimulate epithelial cell differentiation and it appears to control the proliferative-differentiative program from basal to suprabasal cells in the skin. 3, 9 Moreover, KGF has been shown to stimulate proliferation and to exert an anti-apoptotic effect for epithelial cells, which are of major importance for the post-traumatic wound healing. [10] [11] [12] Due to enzymes, proteases, and lack of receptors the local application of growth factors as proteins has been shown to be ineffective. 1 Therefore new technologies needed to be designed to improve wound healing.
A new therapeutic approach to deliver growth factors to skin lesions in order to accelerate dermal and epidermal regeneration is viral or non-viral gene transfer. Nonviral gene therapy has great potential and several advantages over viral gene therapy, such as non-viral delivery systems are easy, simple, direct, inexpensive, do not require ex vivo manipulation and the genes can be administered repeatedly without causing an immune response or tachyphylaxia. 13 Our group has recently determined mechanisms, biodistribution and feasibility after injecting non-viral liposomal cDNA complexes into the skin. 14, 15 We showed that after the injection of liposomal cDNA complexes coding for insulin-like growth factor-I (IGF-I), the transferred gene was transcribed into IGF-I mRNA and translated into the IGF-I protein. 15 The translated IGF-I-protein was not only shown to be physiologically active, but also to be more potent then the same factor administered as a recombinant human IGF-I protein in a 1000-fold higher concentration.
14 Based on these findings we hypothesized that administration of KGF cDNA is a feasible approach and the effects of keratinocyte growth factor on dermal and epidermal regeneration could be augmented by using non-viral liposomal cDNA gene transfer.
Results

Transfection
The fine granular blue-green reaction product of the ␤-galactosidase reaction was predominantly present in the granulation tissue, composed of spindle-shaped fibroblasts, macrophages, multinucleate giant cells and growing small blood vessels underlying the wound indicating preferential transfection of cells with higher proliferation rates ( Figure 1 ). Although most staining for ␤-galactosidase was in the cytoplasm, some reaction products were observed outside the cell boundaries, possibly due to enzymes released by dead cells or the simple diffusion of reaction products (Figure 1 ).
KGF skin concentration
Immunohistochemistry using antibodies against KGF demonstrated KGF expression in the same location of the dermis and epidermis, in which we detected a positive reaction for ␤-galactosidase (Figure 2a, b) . Cells that were identified as positive were fibroblasts, basal cells of the skin, and macrophages. Rats receiving 2.2 g of the KGF cDNA construct demonstrated a significant increase of KGF-positive cells when compared with controls, indicating an increased expression and concentration of KGF, P Ͻ 0.001 ( Figure 3 ).
Epithelial (epidermal) regeneration
Re-epithelialization: Area re-epithelialization, determined by planimetry, was significantly increased in rats receiving the liposomal KGF cDNA complex when compared with rats receiving the liposomes containing the cDNA for ␤-galactosidase. Four weeks after the thermal injury 25 ± 0.8% of the original wound was re-epithelized in the KGF group, whereas only 17 ± 0.7% of the original burn wound was re-epithelized in the liposomal group, P Ͻ 0.0001. Six weeks after burn the percentage of epithelium in the KGF cDNA gene group was 34 ± 1%, compared with 21 ± 0.8 in the liposome group, P Ͻ 0.0001 (Figure 4a ).
Histological examinations of linear re-epithelialization revealed similar results to planimetry. Rats treated with the KGF gene had a linear re-epithelialization of 400 ± 17 m 6 weeks after burn, when compared with rats receiv- ing liposomes 240 ± 19 m, P Ͻ 0.0001 (Figure 4b ). KGF cDNA-treated animals thus demonstrated an increase of almost 170% in epithelium growing from the wound edges on to the granulation tissue.
Epithelial cell layers:
Cell layers in the newly formed epithelium were 15 ± 1 cell layers in the KGF cDNA treated group and 14 ± 1 cell layers in the control group. There was no significant difference between groups, indicating that the differentiating process from basal skin cells to suprabasal skin cells is intact and similar in both groups.
Skin cell proliferation and aopotosis: After the thermal injury skin cell proliferation was increased compared with normal skin. Proliferation was found on both groups at the leading edge and at the neo-epithelium on the former wound bed, as shown in Figure 2c . In KGF cDNA gene transfer in a dose of 2.2 g significantly increased basal cell proliferation by almost 100% at the wound edge and the neo-epithelium when compared with vehicle. Rats receiving KGF exhibited a basal skin cell proliferation of 30%, whereas rats receiving liposomes alone exhibited a proliferation rate of 15%, P Ͻ 0.01 (Figure 2c, d, and 5 ).
In addition, basal skin cell apoptosis was decreased by nearly 100% in the KGF cDNA-treated group compared with vehicle, P Ͻ 0.005 (Figure 2e , f, and 5). Thus, animals receiving the KGF gene had a significant improved net balance calculated as proliferation divided by apoptosis, when compared with liposomes alone, P Ͻ 0.005 ( Figure 5 ).
Dermal regeneration
Collagen morphology and deposition: KGF cDNA gene transfer improved quality and quantity of deposited collagen when compared with vehicle. Rats receiving the Gene Therapy KGF cDNA in a dose of 2.2 g, collagen structure was indexed with 2.5 ± 0.1 and therefore significantly higher than the collagen structure in rats receiving vehicle with 1.8 ± 0.1, P Ͻ 0.05 (Table 1 and Figure 6a , b). The staining intensity of collagen deposition was significantly higher in rats treated with KGF cDNA 2.9 ± 0.1 when compared with vehicle 2.1 ± 0.2, P Ͻ 0.05 (Table 1 and Figure 6a , b). We further found that KGF cDNA at 2.2 g increased the length of the collagen pannus, KGF cDNA 340 ± 30 m versus vehicle 200 ± 10 m, and with the same depth of the area of the collagen pannus was significantly increased in rats treated with KGF cDNA when compared to vehicle, P Ͻ 0.05 (Table 1 and Figure 6c , d).
Neo-angiogenesis:
KGF cDNA treatment increased the number of blood vessels per high power field, and thus 
IGF-I concentration
Immunohistochemistry using antibodies against IGF-I demonstrated IGF-I expression in dermal and epidermal structures. Cells that were identified as positive were fibroblasts, basal cells of the skin, and macrophages. Rats receiving 2.2 g of the KGF cDNA construct demonstrated a significant increase of IGF-I positive cells 7 ± 0.7, when compared with positive cells in control animals 3 ± 0.3, indicating an increased expression and concentration of IGF-I, P Ͻ 0.001.
Discussion
Wound healing is a dynamic interactive and complex process involving soluble mediators, blood cells, extracellular matrix, and parenchymal cells. 1 Wound healing is divided into three phases: inflammation, tissue formation and tissue remodeling. During all these phases, different cell types synthesize and release different mediators that modulate and stimulate the cascade of wound healing. These mediators encompass chemokines and growth factors. In animal models growth factors have been shown to influence and enhance epidermal and dermal regeneration. 1, 2 In humans, growth factors have failed so far to show their efficacy. 2 This failure may be due to a high concentration of proteases in wounds, which rapidly destroy the protein applied to the wound. 16 In addition, receptors for the growth factors are decreased, thus the application of recombinant human growth factors as proteins cannot be effective, because there are no receptors that the growth factors can bind to initiate the signal cas- cade for effects. New therapeutic strategies needed to be designed to improve the efficacy of growth factor application and consecutive epidermal and dermal regeneration, one of which is non-viral liposomal gene therapy.
Only few studies have been performed to determine non-viral liposomal gene transfer to the skin for the delivery of growth factors.
14,15,17 Sun et al 17 administered a-FGF topically plus subcutaneously injection on a daily basis in diabetic mice with incisional wounds. The authors found that transfection with a-FGF increased wound breaking strength and improved wound quality when compared to controls. Our group studied the effects of IGF-I on wound healing and determined mechanisms and biodistribution after injecting the liposomal cDNA coding for IGF-I into the skin. 14, 15 We showed in the earlier, as well as the present study that after the injection of liposomal cDNA complexes transfection occurred in myofibroblasts, endothelial cells, and macrophages, including multinucleate giant cells, all of which are known to be proliferative. The transferred gene was transcribed into mRNA and translated into the protein. 15 The translated protein was not only shown to be physiologically active, but also to be more potent than the same factor administered as a recombinant protein in a 1000-fold higher concentration. 14 Based on these data we concluded that non-viral liposomal gene transfer encapsulating the cDNA coding for growth factors to enhance wound healing is an approach that may be more effective than the application of growth factors as the recombinant protein. Based on these findings we studied the effect of keratinocyte growth factor (KGF) cDNA driven by a cytomegalovirus (CMV) promoter encapsulated in cationic liposomes into acute wounds, which were induced by a thermal unjury.
KGF is synthesized by several mesenchymal cells, such as fibroblasts, microvascular endothelial cells, and smooth muscle cells. 6, 7 For KGF to exert its effects, which are mainly paracrine, KGF needs to bind to its receptor FGFR2-IIIb, which is expressed in keratinocytes and hair follicles. 8, 18 Activating the KGF-receptor leads through phosphorylation to proliferation of epithelial cells and is responsible for the morphogenesis of the skin and thus plays an important role during wound healing. 3 One day after wounding, KGF mRNA concentration were more than 150-fold higher compared with basal levels. 10 The KGF mRNA was mainly present in the dermal fibroblasts below the wound and at the wound edges, whereas KGF Gene Therapy receptor transcripts and also the corresponding protein were exclusively detected in keratinocytes of the epidermis and the hair follicles.d These cells migrate over the wound and subsequently proliferate, which leads to complete wound re-epithelialization. 19 The importance of KGF during wound healing was further demonstrated in follow-up studies in healing-impaired animals, which was associated with attenuated KGF levels.
20 FGFR2-IIIb transgenic null mice showed a severe delay in re-epithelialization, which was associated with a reduced proliferation rate of basal keratinocytes. We showed in agreement with others, that KGF enhanced re-epithelialization of the wound by nearly 170%. Based on our findings we suggest that accelerated wound healing was due to increased proliferation and decreased apoptosis of basal epithelial cells. The proliferative and anti-apoptotic effects of KGF is probably due a stimulation of Bcl-2, a general antagonist of apoptosis 21 and stimulation of the p65 subunit of nuclear factor-kappa B (NF-B), which also acts as an anti-apoptotic and pro-mitogenic signal. 22 There is also evidence from our group that KGF decreases caspase-3, which is an apoptotic death signal (unpublished observations). KGF cDNA did not inhibit the differentiation process of keratinocytes, as we found no differences in epithelial cell layers, which was also found after administering exogenous KGF protein to the wound. 23 We can conclude that the accelerated migration of epithelium on to the wound bed is associated with a stimulation of keratinocyte proliferation and inhibition of keratinocyte apoptosis.
KGF has been described to affect mostly epithelial structures, however, there is evidence that KGF also affects the underlying mesenchymal cells, and in turn epidermal and dermal structures. 8 Therefore, in the present study, we examined the effect of KGF on epithelial and mesenchymal structures. We found that KGF cDNA gene transfer increased the length and area of the collagen pannus deposited from the wound edge into the newly formed skin. KGF did not only affect the length of the collagen pannus, also the morphology of the collagen deposition. KGF cDNA increased the amount of collagen at the wound site and the structure of the newly formed collagen was similar to the physiological structure of collagen. Increased and improved collagen formation may be due to a stimulation of fibroblasts to increase their synthesis capacity. The increase of collagen at the wound edge can explain the increased wound breaking strength as found in many different studies. A new finding was that KGF stimulated other mesenchymal growth factors, such as IGF-I. In the present study we demonstrated that KGF increased IGF-I expression. Therefore we hypothesize, that KGF is not acting through a narrow specific window, but through interaction and stimulation of other growth factors.
The development of a vascular supply is essential for wound healing and reliant on neo-vascularization. During wound healing, angiogenic capillary sprouts invade the fibrin/fibronectin-rich wound and within a few days organize into a microvascular network in the granulation tissue. 24 Neo-vascularization depends on a dynamic interaction between endothelial cells, cytokines and the extracellular matrix. 25 Vascular endothelial growth factor (VEGF) stimulates and increases neo-vascularization. 25 Chronic wounds, or impaired wound have decreased concentrations of VEGF and fewer blood vessels in the 
b) Representative section of an animal with control treatment. The collagen staining is less intense and the structure more linear when compared with panel (a). Magnification ×200. (c) Representative section of a rat treated with KGF cDNA with a small magnification. The green-stained dermal pannus spread from the edge of normal 'unwounded' skin (to the right a hair follicle can be identified) throughout the whole section, indicating a large area of collagen composed dermal matrix. Magnification ×40. (d) Only a week and short collagen pannus can be identified to have formed into the wound bed of control rats. Magnification ×40. (e) Histologic section of rat skin treated with KGF cDNA and stained with H and E. Many newly formed blood vessels were identified in the dermal matrix. Magnification ×400. (f) In control animals only few blood vessels could be found, thus having low neo-angiogenesis of the dermal bed underlying the wound. Magnification ×400.
granulation tissue when compared with physiologic wounds, which is probably due to increased proteolysis of VEGF. 26, 27 In the present study we found, that KGF cDNA transfer increased the concentration of newly formed blood vessels in the granulation tissue. Supporting this finding is the increased concentration of VEGF, which we showed by immunohistochemical staining with antibodies against VEGF. KGF increased VEGF concentration in the wound, which in turn leads to increased angiogenesis. This may be one of the mechanisms by which KGF improves mesenchymal and dermal structures.
In the present study, we showed that KGF cDNA gene transfer is a feasible approach to improve dermal and epidermal regeneration. KGF cDNA accelerated re-epithelialization by nearly 170% through increased proliferation and decreased apoptosis of keratinocytes. KGF cDNA gene transfer stimulates fibroblasts to synthesize more and better collagen at the wound edge. Nutritional support of the newly formed wound is due to enhanced and increased neo-vascularization of the granulation tissue, which is due to increased VEGF concentration. As KGF plays an essential role during wound healing and given the advantages of non-viral gene transfer, we con- clude that non-viral gene transfer of KGF cDNA would be an efficient approach to improve wound healing.
Materials and methods
Twenty-two adult male Sprague-Dawley rats (350-375 g) were placed in wire-bottom cages housed in a temperature-controlled room with a 12-h light-dark cycle. Rats were acclimatized to their environment for 7 days before the blinded study. All animals received similar amounts of a liquid diet of Sustacal (Mead Johnson Nutritionals, Evansville, IN, USA) and water ad libitum throughout the study. Each rat received a 30% total body surface area (TBSA) full-thickness scald burn under general anesthesia (pentobarbital 50 mg/kg body weight) and analgesia (buprenorphin 1 mg/kg body weight) following a modified procedure as previously described. 28 After the thermal injury rats were immediately resuscitated by intraperitoneal injection of Ringer's lactate (50 ml/kg body weight). Thermally injured rats were then randomly divided into two groups to receive: (1) weekly subcutaneous injections of liposomes (10 l liposomes in 180 l saline) containing 0.2 g of the reporter gene for ␤-galactosidase LacZ cDNA construct, vehicle, n = 11. (2) Weekly subcutaneous injections of liposomes (10 l liposomes in 180 l saline) containing 2.2 g of a KGF cDNA construct, plus 0.2 g of the reporter gene for ␤-galactosidase LacZ cDNA construct, n = 11.
Immediately after the thermal injury, each rat received 0.2 ml of the lipoplexes subcutaneously injected at two sites opposite from each other. This was repeated each week for 4 weeks. Mixtures were freshly prepared before injection. Animals were humanely killed by decapitation 5 days after the last injection. Skin samples from the back were harvested, fixated in 4% paraformaldehyde, 1% glutaraldehyde, or snap-frozen in liquid nitrogen and stored at Ϫ73°C for analysis.
In previous experiments we found that animals receiving liposomes containing the LacZ gene represented a better control compared with animals receiving saline, in having better wound healing rates and an attenuated Gene Therapy acute phase response. Therefore, in the present study, we chose to use liposomes with LacZ as the control group. The rat KGF cDNA construct consisted of a CMV-driven KGF cDNA plasmid prepared at the UTMB Sealy Center for Molecular Science Recombinant DNA Core Facility. The liposomes were formulated from 1:1 (M/M) DMRIE (1,2-dimyristyloxypropyl-3-dimethyl-hydroxyl ethyl ammonium bromide) and cholesterol suspended in membrane-filtered water (Life Technologies, Rockville, MD, USA). This reagent interacts spontaneously with KGF cDNA to form the lipid cDNA complex. The dose of 2.2 g for the KGF cDNA was defined in a dose response study. 29 
Transfection
Transfection was determined in skin samples taken 33 days after burn and 5 days after the last injection by measuring the presence of ␤-galactosidase. The presence of the ␤-galactosidase protein was detected by histochemical staining with Bluo-Gal (halogenated indolyl-␤-Dgalactoside) (Life Technologies, Gaithersburg, MD, USA) for ␤-galactosidase in the skin. Linear skin biopsies approximately 4 mm thick in width and extended from the center of the burn wound well into the surrounding normal skin were taken at the end of the experiment and processed as previously published. 14, 15 KGF skin concentration KGF protein concentrations in the skin were measured by antibodies against KGF using standard immunohistochemical techniques. Paraffin-embedded samples were cut 4 m in thickness, placed in an increasing alcohol concentration and finally in PBS. Protease K (100 g/ml) was applied at 37°C for 30 min. After washing with PBS endogenous peroxidases were blocked using methanol-H 2 O 2 for 15 min. The samples were then again washed. The primary antibody goat anti-KGF (Santa Cruz Biotechnology, Santa Cruz, CA, USA) was applied to the samples and then incubated at 4°C overnight. After another washing the secondary antibody DAKO E 0466 (biotinylated rabbit anti-goat, 1:400) was incubated for 1 h at 37°C followed by another washing. The samples were then incubated with streptavidin (1:300; DAKO P 0397) for 1 h at 37°C. The samples were thoroughly washed and diaminobenzidine-hydrogen peroxidase was applied for color development. The counterstaining was performed using hematoxylin. After placing the samples in increasing alcohol, they were mounted. 
Epithelial (epidermal) regeneration
Re-epithelialization: Re-epithelialization was determined by planimetry and by histological examinations. Planimetry was performed as follows: the wound eschar was left intact for the first 28 days and then removed by gentle traction, caution being taken not to disturb or destroy the healing edge along the periphery. After removing the eschar, the animals were placed on a standard surface and the wound area was traced on to acetate sheets along the well-demarcated re-epithelialized and non-burned interface and the leading edge of the neo-epithelium. The areas of these tracings were calculated by computerized planimetry (Sigma Scan and Sigma Plot software, San Rafael, CA, USA). The area of re-epithelialization was calculated by the following formula. Values are expressed as percent re-epithelialization from the original burn wound: Epithelialization = (o Ϫ I)/b × 100; with o, outer area 4 or 5 weeks after burn; I, inner area 4 or 5 weeks after burn; b, original area at the time of burn. By using this formula only re-epithelialization, without contraction was calculated.
Histologically, re-epithelialization was determined in skin samples taken 33 days after burn and 5 days after the last injection. Linear skin biopsies were taken and were approximately 4 mm thick in width and extended from the center of the burn wound well into the surrounding normal skin. Skin specimens were fixed overnight at 4°C in 4% paraformaldehyde in a HEPES-buffered Hanks solution at pH 7.6. Skin was then stained for H and E.
30
Length of re-epithelialization was determined by measuring the distance from the normal, uninjured skin (identified by skin appendix structures, such as hair follicle, glands) till the end of the neo-epithelium covering the wound and granulation tissue. Measurements were repeated twice by observers blinded to the treatment. Length was calculated by forming the average of the two measurements.
Epithelial cell layer:
H and E-stained skin samples were examined to determine the highest neo-epidermis. Epithelial cell layer from the basal membrane to the surface were counted by three observers blinded to treatment. The epithelial cell layer was calculated by forming the average of the three measurements.
Skin cell proliferation and apoptosis:
The balance between proliferation and apoptosis is an important indicator for organ homoeostasis, in this case the skin. Skin cell proliferation was determined using antibodies against KI 67. KI 67 stains cells that underwent mitosis over the last 24 h. Paraffin sections 3 to 5 m thick were mounted on 'Superfrost Plus' slides, heated for 20 min at 72°C, deparaffinized and rehydrated. Sections were placed in a microwave for 30 min at 240 W in a citrate buffer at pH = 7.3, then cooled to room temperature. Following antigen retrieval, the slides were rinsed, endogenous peroxidase activity was blocked by using methanolic peroxide, the slides were rinsed again, and primary monoclonal antibody against Ki-67 (BD PharMingen, San Diego, CA, USA; Cat No 36521A) in a dilution of 1:100 was applied. All slides were incubated using a Ventana machine and each antibody incubation was performed at 37°C and labeled streptavidin-biotin-peroxidase method at 37°C was used to visualize positive reaction (Ventana Medical Systems basic DAB detection kit; Ventana Medical Systems, USA). A dark brown nuclear precipitate was evaluated as positive reaction. Crypts of the large bowel were used for positive control. Sections incubated without primary antibody had no detectable immunoreactivity.
All skin cells in the pannus and along the basal layer were counted. Proliferation was then determined by positive-stained skin cells per 100 counted skin cells. Three observers blinded to the treatment groups were recruited to count the cells.
Apoptosis was measured using the TUNEL (terminal deoxyuridine nick end labeling) immunohistochemical method (Apoptag; Oncogene, Baltimore, MD, USA) in order to allow histologic identification of apoptotic cells in the skin. Formalin-fixed tissues were processed and embedded into paraffin. Sections of 4-m, obtained at 40-50 m intervals, were deparaffinized, rehydrated in graded alcohol and washed in deionized water. Protein was digested using proteinase K (20 l/ml in phosphate buffered saline (PBS)) to decrease background contamination. The sections were then incubated with freshly prepared TdT (terminal deoxyribonucleotidyl transferase) enzyme at 37°C for 2 h. Following the enzyme incubation, the slides were incubated with antidigoxigenin peroxidase at room temperature for 30 min. The sections were thoroughly washed and diaminobenzidine-hydrogen peroxidase was applied for color development. Lastly, the sections were counterstained with Mayer's hematoxylin and mounted.
Two sections (4 m) of each block of tissue were obtained at 40 to 50 m intervals. In each section, three observers blinded to treatment counted TUNEL-positive cells. Apoptotic cells were identified as those with a brown staining of the nucleus, or as apoptotic bodies, which are fragments of apoptotic cells engulfed by neighboring epithelial cells. All epithelial cells within the skin were counted and apoptosis was expressed as a percentage of apoptotic cells per hundred epithelial cells. Values for all sections averaged to calculate apoptosis for the apoptotic rate in the skin. Net balance, which determines net cell turnover, was calculated by proliferation/apoptosis.
Dermal regeneration
Collagen morphology and deposition: Quality and quantity of collagen was determined by the Masson Goldner Trichrome staining. 30 Qualitative measurements of the wound collagen were performed by examining the pannus for collagen bundles and the staining intensity of collagen in the area at the wound edge. The collagen morphology and staining intensity were determined by three observers blinded to the treatment. A score from 1 to 4 was given to each samples, whereby 1 = collagen boundless are linear, and 4 = collagen boundless appear to have normal histological structures ('angel curl shape'). Similarly a score from 1 to 4 was given for staining intensity for the collagen pannus, 1 = weak blue-green staining, few collagen concentration, 4 = strong bluegreen staining, high density of collagen in the pannus.
The length of the collagen pannus being deposited in the dermal wound structures was determined by measuring the distance from the normal, uninjured skin till the end of the collagen pannus in the granulation tissue. Measurements were repeated twice by observers blinded to the treatment. Length was calculated by forming the average of the two measurements. Depth of the collagen pannus was determined in the same fashion. The area of the collagen pannus was calculated by multiplying the length × the depth of the pannus.
Neo-angiogenesis and vascular endothelial growth factor (VEGF)
Neo-angiogenesis was determined by quantifying blood vessels in the granulation tissue and by immunohistochemical staining with antibodies against vascular endo-thelial growth factor (VEGF). Three observers blinded to treatment counted the blood vessels in three different sections of the granulation tissue using a magnification of ×40 (high power field). Values were averaged and calculated as blood vessels per m 2 . VEGF protein concentrations in the skin were measured by antibodies against VEGF using standard immunohistochemical techniques. Paraffin-embedded samples were cut 4 m in thickness, placed in an increasing alcohol concentration and finally in PBS. Pre-treatment in microwave for 30 min at 240 W. After washing with PBS endogenous peroxidases were blocked using methanol-H 2 O 2 for 15 min. The samples were then again washed. The primary antibody rabbit anti-VEGF (PC 315, Oncogene Research Products, 1:50) was applied to the samples and then incubated at 4°C overnight. After another washing the secondary antibody (DAKO E0431 biotinylated anti-rabbit, 1:300) was incubated for 1 h at 37°C followed by another washing. The samples were then incubated with streptavidin (1:300; DAKO P 0397) for 1 h at 37°C and again washed. The counterstaining was performed with hematoxylin. After placing the samples in an increasing alcohol row they were embedded. Positive controls used the blood vessels of the small bowel. VEGF concentration was determined by the number of positive cells per blood vessel. Three observers blinded for treatment counted each sample at three different sites for VEGF positive cells.
IGF-I concentration
Insulin like-growth factor-I (IGF-I) protein concentrations in dermal and epidermal structures were measured by antibodies against IGF-I using standard immunohistochemical techniques. Paraffin-embedded samples were cut 4 m in thickness, placed in an increasing alcohol concentration and finally in PBS. Protease K (100 g/ml) was applied at 37°C for 30 min. After washing with PBS endogenous peroxidases were blocked using methanol-H 2 O 2 for 15 min. The samples were then again washed. Samples were incubated with pig serum (1:5, DAKO X901) for 20 min. After washing the primary antibody rabbit anti-IGF-I (1:10, Peprotech, TEBU, Germany) was applied to the samples and then incubated at 4°C twice overnight. After another washing, the secondary antibody DAKO E 431 (biotinylated swine anti-rabbit, 1:300) was incubated for 1 h at 37°C followed by another washing. The samples were then incubated with streptavidin (1:300; DAKO P 0397) for 1 h at 37°C. The samples were thoroughly washed and diaminobenzidine-hydrogen peroxidase was applied for color development. The counterstaining was performed using hematoxylin. After placing the samples in increasing alcohol, they were mounted.
IGF-I concentration was determined by the number of positive cells per high power field (HPF) and per m 
Ethics and statistics
These studies were reviewed and approved by the Animal Care and Use Committee of the University of Regensburg, Bavaria and Regierung der Oberpfalz, Bayern, Germany assuring that all animal received humane care according to the criteria outlined in the Guide for the Care and Use of Laboratory Animals, published by Gene Therapy the National Institutes of Health. Statistical comparisons were made by analysis of variance (ANOVA) and Student's t test with the Bonferroni correction. Data are expressed as means ± standard error of the mean (s.e.m.). Significance was accepted at P Ͻ 0.05.
